NCCN Awarded $2 Million in Research Funding from Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.FORT WASHINGTON, PA —The National Comprehensive Cancer Network ® (NCCN ®) Oncology Research Program (ORP ) has been awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to study bavituximab, a first-in-class treatment approach for various cancers. “NCCN is very pleased to collaborate with Peregrine Pharmaceuticals on